Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors
- 13 February 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 135 (7), 510-513
- https://doi.org/10.1182/blood.2019003570
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemiaBlood, 2019
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLThe New England Journal of Medicine, 2018
- Depth of response and progression free survival in CLL patients on ibrutinib.Journal of Clinical Oncology, 2018
- Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic LeukemiaJAMA Oncology, 2018
- The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodiesHaematologica, 2017
- Tumour-associated macrophages as treatment targets in oncologyNature Reviews Clinical Oncology, 2017
- Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemiaOncotarget, 2016
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2016
- The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapiesSeminars in Cancer Biology, 2014
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008